Population survey of CCR5 Δ32, CCR5 m303, CCR2b 64I, and SDF1 3′A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups

被引:39
|
作者
Wang, FS
Hong, WG
Cao, YZ
Liu, MX
Jin, L
Hu, LP
Wang, Z
Feng, TJ
Hou, J
Zhang, B
Shi, M
Xu, DP
Lei, ZY
Wang, B
Liu, ZD
Ye, JJ
Peng, L
Qiu, Y
Winkler, C
机构
[1] Beijing Hosp Infect Dis, Beijing Inst Infect Dis, Div Biol Engn, Beijing, Peoples R China
[2] Natl Ctr AIDS Prevent & Control, Beijing, Peoples R China
[3] Inst Med Informat, Div Med Stat, Beijing, Peoples R China
[4] Hlth & Antiepidem Ctr Henan Province, Zhengzhou, Peoples R China
[5] Shenzhen Hlth & Antiepidem Stn, Shenzhen, Guangdong Prov, Peoples R China
[6] Hlth & Antiepidem Ctr Xin Jiang Autonomous Reg, Mulomuqi, Peoples R China
[7] Sci & Technol Inst Family Planning, Kunming, Yunnan Province, Peoples R China
[8] NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21701 USA
关键词
coreceptors; SDF-1; CCR2; CCR5; HIV-1; allele frequency;
D O I
10.1097/00126334-200302010-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of this study is to determine in indigenous Chinese ethnic groups the frequencies of the chemokine (SDFI 3'A) and chemokine receptors (CCR5 Delta32, CCR5 m303, and CCR2b 641) HIV-1/AIDS restriction alleles. The study includes two cohorts; the first comprised 3165 indigenous healthy subjects representing eight ethnic groups: Han (n = 1406), Uygur (n = 316), Mongolia (n = 134), Hui (n = 386), Tibetan (n = 330), Zhuang (n = 378), Dai (n = 101), and Jingbo (n = 114). The second cohort consisted of 330 HIV-1-infected (86 subjects infected by sexual transmission and 198 subjects infected by HIV-1-contaminated blood or by sharing injection equipment; the remaining 46 subjects said nothing about HIV-1 transmission) and 474 HIV-1-uninfected Han Chinese belonging to one of two HIV-1 high-risk groups: intravenous drug users (n = 215) and individuals with sexually transmitted diseases (n = 259). Genotypes for the four genes were obtained using PCR (CCR5 Delta32) or PCR-restriction fragment length polymorphism. Randomly selected amplified PCR products were further confirmed by direct DNA sequencing. The variant allele frequencies were determined to be 0% to 3.48% for CCR5 Delta32, 0% for CCR5 m303, 16.23% to 28.79% for CCR2b 641, and 17.70% to 27.76% for SDFI 3'A in Chinese healthy individuals from eight ethnic groups. These findings show that allele frequencies differ among the eight Chinese ethnic groups for CCR5 Delta32, CCR2b 641, and SDFI 3'A and that the CCR5 m303 and CCR5 Delta32 mutant alleles were absent or infrequent in Chinese, which may be helpful for studies of specific anti-HIV-1 vaccine trials and coreceptor inhibitor drug targets in Chinese populations. Furthermore, we observed no significant differences in allele or genotypic frequencies between HIV-1-infected and HIV-1-uninfected groups from the Han ethnic group. Our finding is the first reporting that there is likely no effect of the examined polymorphisms in our study on HIV-1 transmission in the Chinese Han population, However, the genetic effects of these and other AIDS-modifying polymorphisms on the pathogenesis and clinical outcome of HIV-1/AIDS diseases is under investigation in Chinese populations.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 48 条
  • [41] Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
    Skerlj, Renato
    Bridger, Gary
    Zhou, Yuanxi
    Bourque, Elyse
    McEachern, Ernest
    Langille, Jonathan
    Harwig, Curtis
    Veale, Duane
    Yang, Wen
    Li, Tongshong
    Zhu, Yongbao
    Bey, Michael
    Baird, Ian
    Sartori, Michael
    Metz, Markus
    Mosi, Renee
    Nelson, Kim
    Bodart, Veronique
    Wong, Rebecca
    Fricker, Simon
    Mac Farland, Ron
    Huskens, Dana
    Schols, Dominique
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6950 - 6954
  • [42] Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
    Skerlj, Renato
    Bridger, Gary
    Zhou, Yuanxi
    Bourque, Elyse
    Langille, Jonathan
    Di Fluri, Maria
    Bogucki, David
    Yang, Wen
    Li, Tongshuang
    Wang, Letian
    Nan, Susan
    Baird, Ian
    Metz, Markus
    Darkes, Marilyn
    Labrecque, Jean
    Lau, Gloria
    Fricker, Simon
    Huskens, Dana
    Schols, Dominique
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) : 2450 - 2455
  • [43] Better CD4+T Cell Recovery in Brazilian HIV-Infected Individuals Under HAART Due to Cumulative Carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-Promoter 59029A/G Polymorphisms
    Rigato, Paula O.
    Hong, Marisa A.
    Casseb, Jorge
    Ueda, Mirthes
    de Castro, Isac
    Benard, Gil
    Duarte, Alberto J. S.
    CURRENT HIV RESEARCH, 2008, 6 (05) : 466 - 473
  • [44] Lack of effect of chemokine receptor CCR2b gene polymorphism (64I) on HIV-1 plasma RNA viral load and immune activation among HIV-1 seropositive female workers in Abidjan, Cote d'Ivoire
    Adjé, CA
    Bilé, CE
    Kestens, L
    Koblavi-Deme, S
    Ghys, PD
    Maurice, C
    Kalou-Badirou, M
    Kabran, N
    Ekpini, RE
    Roels, TH
    Wiktor, SZ
    Nkengasong, JN
    JOURNAL OF MEDICAL VIROLOGY, 2001, 64 (04) : 398 - 401
  • [45] Changes in the V3 region of gp 120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Δ32 heterozygote
    Gorry, Paul R.
    Dunfee, Rebecca L.
    Mefford, Megan E.
    Kunstman, Kevin
    Morgan, Tom
    Moore, John P.
    Mascola, John R.
    Agopian, Kristin
    Holm, Geoffrey H.
    Mehle, Andrew
    Taylor, Joann
    Farzan, Michael
    Wang, Hui
    Ellery, Philip
    Willey, Samantha J.
    Clapham, Paul R.
    Wolinsky, Steven M.
    Crowe, Suzanne M.
    Gabuzda, Dana
    VIROLOGY, 2007, 362 (01) : 163 - 178
  • [46] Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotype
    Zaunders, John
    Dyer, Wayne B.
    Churchill, Melissa
    Munier, C. Mee Ling
    Cunningham, Philip H.
    Suzuki, Kazuo
    McBride, Kristin
    Hey-Nguyen, Will
    Koelsch, Kersten
    Wang, Bin
    Hiener, Bonnie
    Palmer, Sarah
    Gorry, Paul R.
    Bailey, Michelle
    Xu, Yin
    Danta, Mark
    Seddiki, Nabila
    Cooper, David A.
    Saksena, Nitin K.
    Sullivan, John S.
    Riminton, Sean
    Learmont, Jenny
    Kelleher, Anthony D.
    JOURNAL OF VIRUS ERADICATION, 2019, 5 (02) : 73 - 83
  • [47] Analysis of the CCR2-64I (rs1799864) genetic polymorphism distribution and its effect on the risk of HIV-1 infection and immunovirological outcomes in Moroccan ART-treated individuals
    Farissi, Fatima Zahra
    Annaz, Hicham El
    Melloul, Marouane
    Alaoui, Moulay Abdelaziz El
    Tagajdid, Mohamed Reda
    Abi, Rachid
    Amine, Sanaa Alaoui
    Marda, Asmaa
    Boui, Mohamed
    Fahime, El Mostapha El
    Mrani, Saad
    GENE REPORTS, 2020, 20
  • [48] Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
    Ogert, Robert A.
    Hou, Yan
    Ba, Lei
    Wojcik, Lisa
    Qiu, Ping
    Murgolo, Nicholas
    Duca, Jose
    Dunkle, Lisa M.
    Ralston, Robert
    Howe, John A.
    VIROLOGY, 2010, 400 (01) : 145 - 155